At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 229 enrolled
Drug / intervention
MenACWY-TTbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE IIIB, OPEN STUDY TO EVALUATE THE IMMUNOGENICITY, REACTOGENICITY AND SAFETY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER HEALTHY SUBJECTS AGED 11-17 YEARS RECEIVED EITHER MENACWY-TT VACCINE (NIMENRIX(REGISTERED)) OR MENCEVAX ACWY(REGISTERED).
In Brief
A Phase 3 clinical trial evaluating MenACWY-TT for Meningococcal ACWY Disease. Completed, enrolled 229 participants across 1 site.
Detailed Summary
This study will evaluate the immunogenicity, reactogenicity and safety of a booster dose of MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received either MenACWY-TT vaccine (Nimenrix) or Mencevax ACWY
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningococcal ACWY Disease
CountriesPhilippines
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartAug 2017
Primary CompletionApr 2018
TodayJul 2026
First PostedJun 16, 2017
Enrollment StartAug 1, 2017
Primary CompletionApr 11, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.0 years ago
Interventions
MenACWY-TTbiological
Single dose of MenACWY-TT given 10 years after first vaccine with either MenACWY-TT or Mencevax ACWY